Related Experiment Videos
[Therapy of solid tumors using high-dose methotrexate and citrovorum factor]
Osterreichische Zeitschrift Fur Onkologie. Austrian Journal of Oncology
|January 1, 1977
Summary
Methotrexate (MTX) chemotherapy is effective for malignant tumors when leucovorin (CF) rescue is limited to 7% of the MTX dose. Lower CF doses correlate with higher objective tumor regression rates in patients.
Area of Science:
- Oncology
- Pharmacology
- Cancer Therapeutics
Context:
- High-dose Methotrexate (MTX) is a chemotherapy agent used for various malignant tumors.
- Optimizing MTX efficacy requires careful management of its toxicity through rescue protocols.
- Citrovorum Factor (CF) rescue is crucial for mitigating MTX-induced side effects.
Purpose:
- To evaluate the efficacy of Methotrexate (MTX) in treating malignant tumors.
- To determine the optimal dosage and infusion duration for MTX therapy.
- To investigate the relationship between the dose of leucovorin (CF) rescue and therapeutic outcomes.
Summary:
- Thirty-eight patients with malignant tumors received MTX (250-1100 mg/m2) via 6-hour or 75-minute infusions.
- Seven different MTX doses and CF rescue schedules were assessed, with CF rescue initiated 2 hours after MTX infusion.
- Objective tumor regressions were observed in 9 out of 14 patients when CF rescue was less than 7% of the MTX dose, indicating efficacy at this level.
Impact:
- Establishes a critical threshold for CF rescue dosage relative to MTX administration to maximize therapeutic success.
- Highlights the potential for significant tumor regression with optimized MTX and CF rescue protocols.
- Underscores the need for further research to refine MTX-based chemotherapy regimens for improved cancer treatment.